secwatch.observer — SEC 8-K summary
======================================

Issuer:     Orchestra BioMed Holdings, Inc. (OBIO)
CIK:        0001814114
Form:       8-K
Filed at:   2025-11-13T23:59:59+00:00
Accession:  0001104659-25-110907
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Orchestra BioMed secures $147M+ funding; BACKBEAT enrollment mid-2026
---------------------------------------------------------------------

- Over $147M in strategic financing since August 2025; Ligand commits additional $31.6M for royalty interest.
- Terumo pays $30M for ROFR on Virtue SAB global coronary market; total Terumo payments $65M.
- BACKBEAT hypertension pivotal trial (N=500) enrollment completion expected mid-2026.
- Virtue Trial (coronary ISR) IDE approved, N=740, initiated in 2H 2025.
- Cash runway expected through Q4 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1814114/000110465925110907/0001104659-25-110907-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1814114/000110465925110907/tm2531129d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-110907

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer